University of Notre Dame du Lac’s BioMarin Pharmaceuticals BMRN Stock Holding History

University of Notre Dame du Lac’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,336	Closed	-$1.04M	–	38
2020 Q1	$1.04M	Sell	12,336 -309	-2%	-$26.6K	0.32%	39
2019 Q4	$1.07M	Buy	12,645 +234	+2%	+$17.7K	0.34%	41
2019 Q3	$837K	Sell	12,411 -28,887	-70%	-$2.22M	0.25%	47
2019 Q2	$3.54M	Sell	41,298 -13,956	-25%	-$1.19M	0.8%	50
2019 Q1	$4.91M	Buy	55,254 +6,135	+12%	+$569K	1.1%	38
2018 Q4	$4.18M	Sell	49,119 -4,774	-9%	-$454K	1.01%	41
2018 Q3	$5.23M	Sell	53,893 -8,089	-13%	-$807K	0.97%	42
2018 Q2	$5.84M	Sell	61,982 -4,599	-7%	-$403K	1.13%	41
2018 Q1	$5.4M	Buy	66,581 +2,243	+3%	+$192K	1%	42
2017 Q4	$5.74M	Buy	64,338 +3,252	+5%	+$283K	1.19%	45
2017 Q3	$5.68M	Buy	61,086 +7,120	+13%	+$629K	1.58%	14
2017 Q2	$4.9M	Sell	53,966 -2,068	-4%	-$188K	1.45%	13
2017 Q1	$4.92M	Buy	+56,034	New	+$4.99M	1.23%	45

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

University of Notre Dame du Lac's BMRN Position: Q2 2020 in Review

University of Notre Dame du Lac sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 12,336 shares — an estimated $1.04M sold.

University of Notre Dame du Lac first reported a position in BMRN in Q1 2017 and held it in 13 quarters. The position peaked at $5.84M in Q2 2018. 528 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

University of Notre Dame du Lac reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
University of Notre Dame du Lac sold 12,336 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $1.04M.
University of Notre Dame du Lac first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 13 quarters.
University of Notre Dame du Lac's BioMarin Pharmaceuticals position peaked at $5.84M in Q2 2018.
528 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on University of Notre Dame du Lac's 13F filing for Q2 2020, filed 14 Aug 2020.